The results showed that Beclin 1 (OR = 2.882), EGFR (OR = 1.672), ALK (OR = 6.982) mutations and tumor differentiation grade (OR = 2.212), TNM stage (OR = 2.772) and lymph node metastasis (OR = 6.222) were independently associated with PFS in the patients with NSCLS (Table 4), and high Beclin 1 expression and negative EGFR and ALK mutations were associated with shorter PFS (Table 4). This evidence concerns the gene ALK and metastatic malignant neoplasm in the lymph nodes.